Index RUT
P/E -
EPS (ttm) -0.07
Insider Own 0.31%
Shs Outstand 130.62M
Perf Week -5.00%
Market Cap 1.46B
Forward P/E 25.32
EPS next Y 0.44
Insider Trans -18.35%
Shs Float 130.21M
Perf Month -9.67%
Income -6.39M
PEG -
EPS next Q -0.02
Inst Own 96.83%
Short Float 14.24%
Perf Quarter -15.84%
Sales 232.28M
P/S 6.30
EPS this Y 607.60%
Inst Trans -1.82%
Short Ratio 9.43
Perf Half Y -19.58%
Book/sh 4.80
P/B 2.33
EPS next Y 74.44%
ROA -0.64%
Short Interest 18.54M
Perf Year 6.26%
Cash/sh 5.68
P/C 1.97
EPS next 5Y -
ROE -1.06%
52W Range 10.06 - 15.15
Perf YTD -19.81%
Dividend Est. -
P/FCF 15.18
EPS past 5Y 54.52%
ROI -0.73%
52W High -26.01%
Beta 1.30
Dividend TTM -
Quick Ratio 12.96
Sales past 5Y 239.63%
Gross Margin 78.40%
52W Low 11.43%
ATR (14) 0.31
Dividend Ex-Date -
Current Ratio 13.81
EPS Y/Y TTM -102.20%
Oper. Margin -14.66%
RSI (14) 33.15
Volatility 2.83% 2.42%
Employees 408
Debt/Eq 0.41
Sales Y/Y TTM -67.86%
Profit Margin -2.75%
Recom 1.40
Target Price 25.40
Option/Short Yes / Yes
LT Debt/Eq 0.41
EPS Q/Q -99.65%
Payout -
Rel Volume 0.95
Prev Close 11.17
Sales Surprise 5.46%
EPS Surprise 100.00%
Sales Q/Q -69.87%
Earnings May 08 AMC
Avg Volume 1.96M
Price 11.21
SMA20 -5.57%
SMA50 -8.51%
SMA200 -17.09%
Trades
Volume 1,876,092
Change 0.36%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-01-24 Initiated
Goldman
Neutral
$20
Sep-27-22 Initiated
JMP Securities
Mkt Outperform
$22
Jan-06-22 Resumed
Goldman
Buy
$38
Aug-06-21 Initiated
Goldman
Buy
$19
Aug-07-20 Reiterated
H.C. Wainwright
Buy
$14 → $12
Aug-03-20 Reiterated
H.C. Wainwright
Buy
$12 → $14
Jun-15-20 Initiated
Evercore ISI
Outperform
$14
Oct-18-19 Initiated
H.C. Wainwright
Buy
$13
Jul-11-19 Upgrade
Cantor Fitzgerald
Neutral → Overweight
$20
Feb-27-19 Reiterated
Cantor Fitzgerald
Overweight
$32 → $28
May-10-18 Upgrade
JP Morgan
Neutral → Overweight
Mar-08-18 Reiterated
Cantor Fitzgerald
Overweight
$25 → $27
Feb-14-18 Downgrade
JP Morgan
Overweight → Neutral
Sep-25-17 Reiterated
RBC Capital Mkts
Outperform
$26 → $28
Sep-15-17 Initiated
Cantor Fitzgerald
Overweight
$24
Jul-31-17 Upgrade
RBC Capital Mkts
Sector Perform → Outperform
$7 → $26
Jul-31-17 Upgrade
JP Morgan
Neutral → Overweight
May-09-17 Reiterated
RBC Capital Mkts
Sector Perform
$6 → $7
Apr-28-16 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$48 → $17
Apr-27-16 Downgrade
JP Morgan
Overweight → Neutral
Show Previous Ratings
Apr-24-24 04:05PM
Apr-21-24 10:39AM
Mar-04-24 11:53PM
08:28PM
Feb-27-24 06:54PM
10:34AM
Loading…
Feb-23-24 10:34AM
06:38AM
(Thomson Reuters StreetEvents)
Feb-22-24 08:00PM
05:15PM
04:44PM
04:01PM
Feb-08-24 04:15PM
Jan-08-24 10:58PM
09:00AM
Jan-05-24 08:50AM
03:03AM
Loading…
03:03AM
Jan-03-24 06:33PM
Dec-05-23 09:55AM
Nov-24-23 09:40AM
Nov-20-23 05:04PM
Nov-07-23 09:40AM
Nov-04-23 09:02AM
Nov-03-23 12:28PM
10:46AM
05:31AM
Nov-02-23 06:22PM
04:39PM
(Associated Press Finance)
04:01PM
11:23AM
Nov-01-23 12:03PM
10:00AM
Loading…
Oct-30-23 10:00AM
Oct-26-23 04:15PM
12:00PM
10:02AM
Oct-24-23 07:45AM
Oct-19-23 01:15PM
06:32AM
Oct-16-23 09:55AM
08:50AM
Oct-12-23 10:42AM
Oct-11-23 09:24AM
Oct-05-23 05:01AM
Sep-29-23 09:55AM
08:50AM
Sep-28-23 11:18AM
10:48AM
Sep-26-23 11:49AM
Sep-21-23 09:19AM
Sep-20-23 07:51AM
Sep-18-23 09:16AM
Sep-14-23 09:36AM
Sep-12-23 08:26AM
07:54AM
Sep-11-23 12:31PM
08:21AM
Sep-08-23 07:06PM
Sep-07-23 08:43AM
Sep-06-23 04:05PM
09:33AM
Sep-05-23 09:40AM
Sep-04-23 10:51AM
Aug-28-23 09:55AM
Aug-24-23 08:50AM
Aug-22-23 11:56AM
10:18AM
Aug-16-23 01:21PM
Aug-11-23 05:26AM
Aug-10-23 11:50AM
09:55AM
Aug-07-23 03:06PM
(Investor's Business Daily)
Aug-06-23 07:00AM
Aug-04-23 12:53PM
01:00AM
Aug-03-23 06:55PM
05:45PM
04:05PM
Jul-28-23 02:56PM
Jul-27-23 11:19AM
Jul-20-23 04:15PM
Jul-13-23 03:00PM
Jul-12-23 09:55AM
Jun-21-23 08:00PM
Jun-14-23 10:50AM
(Investor's Business Daily)
Jun-13-23 09:07PM
Jun-01-23 07:52PM
May-30-23 04:15PM
May-08-23 04:15PM
May-03-23 09:42AM
(Thomson Reuters StreetEvents) +6.89%
May-02-23 10:00PM
05:35PM
04:37PM
04:05PM
Apr-26-23 08:00PM
Apr-18-23 04:15PM
Apr-09-23 08:52AM
Mar-24-23 06:30AM
Mar-19-23 08:56AM
Mar-01-23 04:15PM
Feb-28-23 08:00AM
Feb-26-23 07:30AM
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Burgess Justin Chief Accounting Officer Mar 01 '24 Option Exercise 10.45 7,101 74,232 20,526 Mar 04 05:25 PM Burgess Justin Chief Accounting Officer Mar 01 '24 Sale 12.78 20,526 262,322 0 Mar 04 05:25 PM Janssen Robert SVP and CMO Jan 04 '24 Option Exercise 9.41 1,500 14,115 51,425 Jan 08 06:48 PM Janssen Robert SVP and CMO Jan 04 '24 Sale 15.00 1,500 22,500 49,925 Jan 08 06:48 PM Novack David F President & COO Jan 02 '24 Option Exercise 5.42 9,000 48,780 12,187 Jan 04 07:04 PM Novack David F President & COO Jan 02 '24 Sale 14.45 9,000 130,050 3,187 Jan 04 07:04 PM Novack David F President & COO Dec 01 '23 Option Exercise 5.42 20,000 108,400 23,187 Dec 05 07:12 PM Novack David F President & COO Dec 01 '23 Sale 13.56 20,000 271,200 3,187 Dec 05 07:12 PM Novack David F President & COO Nov 03 '23 Option Exercise 5.42 20,000 108,400 23,187 Nov 07 05:16 PM Novack David F President & COO Nov 03 '23 Sale 15.00 20,000 300,000 3,187 Nov 07 05:16 PM Novack David F President & COO Nov 01 '23 Option Exercise 5.42 20,000 108,400 23,187 Nov 03 04:32 PM Novack David F President & COO Nov 01 '23 Sale 14.12 20,000 282,400 3,187 Nov 03 04:32 PM Janssen Robert SVP and CMO Oct 10 '23 Option Exercise 9.41 1,755 16,515 51,680 Oct 11 08:53 PM Janssen Robert SVP and CMO Oct 10 '23 Sale 15.01 1,755 26,343 49,925 Oct 11 08:53 PM Novack David F President & COO Oct 02 '23 Option Exercise 5.42 40,000 216,800 43,187 Oct 04 04:35 PM Janssen Robert SVP and CMO Oct 02 '23 Option Exercise 9.41 5,015 47,191 54,940 Oct 03 08:26 PM Novack David F President & COO Oct 02 '23 Sale 14.88 40,000 595,000 3,187 Oct 04 04:35 PM Janssen Robert SVP and CMO Oct 02 '23 Sale 15.03 5,015 75,375 49,925 Oct 03 08:26 PM Novack David F President & COO Sep 01 '23 Option Exercise 5.42 20,000 108,400 23,187 Sep 05 05:05 PM Novack David F President & COO Sep 01 '23 Sale 14.48 20,000 289,600 3,187 Sep 05 05:05 PM Janssen Robert SVP and CMO Aug 24 '23 Option Exercise 9.41 600 5,646 50,525 Aug 25 06:47 PM Janssen Robert SVP and CMO Aug 24 '23 Sale 15.02 600 9,012 49,925 Aug 25 06:47 PM Janssen Robert SVP and CMO Aug 23 '23 Option Exercise 9.41 34,857 328,004 84,782 Aug 24 12:30 PM Janssen Robert SVP and CMO Aug 23 '23 Sale 15.01 34,857 523,204 49,925 Aug 24 12:30 PM Novack David F President & COO Aug 08 '23 Option Exercise 4.41 40,000 176,550 43,187 Aug 10 11:57 AM Janssen Robert SVP and CMO Aug 08 '23 Option Exercise 9.41 2,600 24,466 52,525 Aug 09 07:26 PM Hack Andrew A. F. Director Aug 08 '23 Sale 14.39 1,500,000 21,585,000 915,000 Aug 10 04:31 PM Novack David F President & COO Aug 08 '23 Sale 14.87 40,000 594,900 3,187 Aug 10 11:57 AM Janssen Robert SVP and CMO Aug 08 '23 Sale 15.05 2,600 39,130 49,925 Aug 09 07:26 PM Burgess Justin Chief Accounting Officer Aug 07 '23 Option Exercise 8.16 8,061 65,767 8,061 Aug 08 04:23 PM Burgess Justin Chief Accounting Officer Aug 07 '23 Sale 14.54 8,061 117,247 0 Aug 08 04:23 PM Hack Andrew A. F. Director Jun 14 '23 Sale 12.68 500,000 6,340,000 2,415,000 Jun 16 04:30 PM Hack Andrew A. F. Director May 18 '23 Sale 10.55 1,000,000 10,550,000 2,915,000 May 19 04:30 PM Novack David F President & COO May 04 '23 Sale 10.90 17,515 190,914 3,187 May 05 08:58 PM
Index RUT
P/E -
EPS (ttm) -2.16
Insider Own 49.00%
Shs Outstand 58.63M
Perf Week 6.53%
Market Cap 4.28B
Forward P/E -
EPS next Y -3.34
Insider Trans -4.20%
Shs Float 32.71M
Perf Month -12.76%
Income -126.22M
PEG -
EPS next Q -0.66
Inst Own 61.15%
Short Float 20.95%
Perf Quarter -12.37%
Sales 0.00M
P/S -
EPS this Y -32.59%
Inst Trans -1.04%
Short Ratio 14.22
Perf Half Y 26.65%
Book/sh 10.94
P/B 6.11
EPS next Y -16.01%
ROA -20.78%
Short Interest 6.85M
Perf Year 90.16%
Cash/sh 11.24
P/C 5.95
EPS next 5Y -
ROE -21.70%
52W Range 33.03 - 89.39
Perf YTD -9.15%
Dividend Est. -
P/FCF -
EPS past 5Y -72.54%
ROI -18.02%
52W High -25.20%
Beta 1.36
Dividend TTM -
Quick Ratio 22.83
Sales past 5Y 0.00%
Gross Margin -
52W Low 102.42%
ATR (14) 2.92
Dividend Ex-Date -
Current Ratio 22.83
EPS Y/Y TTM -31.75%
Oper. Margin 0.00%
RSI (14) 41.75
Volatility 3.64% 4.06%
Employees 92
Debt/Eq 0.00
Sales Y/Y TTM -
Profit Margin -
Recom 1.10
Target Price 101.11
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q -26.40%
Payout -
Rel Volume 0.48
Prev Close 66.07
Sales Surprise -
EPS Surprise -2.99%
Sales Q/Q -
Earnings Feb 27 BMO
Avg Volume 482.01K
Price 66.86
SMA20 -2.11%
SMA50 -13.24%
SMA200 6.17%
Trades
Volume 230,261
Change 1.20%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-17-24 Initiated
Jefferies
Buy
$97
Apr-01-24 Upgrade
Leerink Partners
Market Perform → Outperform
$69 → $110
Feb-28-24 Resumed
Guggenheim
Buy
$99
Feb-23-24 Initiated
Robert W. Baird
Outperform
$105
Sep-27-23 Initiated
Stifel
Buy
$65
Aug-08-23 Initiated
SVB Securities
Market Perform
$42
Jul-24-23 Initiated
Guggenheim
Buy
$56
Jan-18-23 Initiated
Wedbush
Outperform
$39
Jun-24-22 Initiated
BMO Capital Markets
Outperform
$28
Apr-08-24 04:30PM
Apr-05-24 07:00PM
06:30PM
Mar-29-24 07:01PM
Mar-25-24 07:01PM
07:01PM
Loading…
Mar-19-24 07:01PM
Mar-05-24 04:52PM
Feb-29-24 04:32AM
Feb-27-24 06:30AM
06:15AM
Feb-22-24 04:00AM
Feb-12-24 06:30AM
Feb-01-24 06:30AM
Jan-08-24 06:30AM
Dec-22-23 03:01PM
01:01PM
Loading…
Dec-21-23 01:01PM
06:30AM
Nov-14-23 07:15PM
06:30AM
Nov-04-23 07:02AM
Nov-01-23 06:30AM
Oct-23-23 02:50AM
Oct-17-23 06:27PM
Oct-16-23 09:55PM
07:30AM
Oct-13-23 06:30AM
Oct-07-23 01:00AM
Oct-05-23 07:13PM
10:29AM
01:01AM
04:13PM
Loading…
Oct-04-23 04:13PM
12:21PM
Sep-18-23 06:30AM
Sep-05-23 06:30AM
Aug-31-23 06:30AM
Aug-17-23 06:40AM
Aug-10-23 06:30AM
Aug-08-23 10:02AM
Aug-01-23 06:30AM
Jul-21-23 08:50AM
Jun-07-23 08:50AM
May-24-23 06:30AM
May-11-23 06:30AM
Apr-19-23 06:30AM
Apr-18-23 09:00AM
Apr-02-23 10:56AM
Mar-23-23 06:30AM
Mar-16-23 06:30AM
Mar-14-23 05:59PM
Mar-01-23 06:30AM
Jan-04-23 06:30AM
Jan-02-23 09:40AM
Dec-13-22 10:15AM
Dec-12-22 03:44PM
Dec-02-22 08:50AM
Nov-17-22 12:00PM
Nov-10-22 06:30AM
Nov-03-22 08:13PM
Oct-31-22 09:14PM
07:15AM
Oct-28-22 04:18PM
(American City Business Journals) +60.64%
04:06PM
(Investor's Business Daily)
11:10AM
12:01AM
Oct-26-22 06:30AM
Oct-23-22 09:26AM
Oct-17-22 06:30AM
Oct-06-22 06:30AM
Sep-20-22 10:16AM
Sep-07-22 06:30AM
Sep-01-22 06:30AM
Aug-10-22 06:30AM
Aug-05-22 06:30AM
Aug-03-22 06:30AM
Jul-20-22 06:30AM
Jul-13-22 06:30AM
Jul-01-22 10:52AM
Jun-21-22 06:30AM
Jun-02-22 06:38AM
May-16-22 09:10AM
May-12-22 06:30AM
Apr-11-22 07:21AM
Apr-08-22 01:15PM
Apr-07-22 06:30AM
Mar-31-22 06:30AM
Mar-29-22 06:30AM
Mar-08-22 05:38PM
Mar-02-22 06:30AM
Feb-03-22 06:30AM
Jan-07-22 06:30AM
Jan-04-22 06:30AM
Nov-10-21 06:30AM
Oct-29-21 09:55AM
Oct-07-21 09:21AM
Sep-08-21 06:30AM
Aug-06-21 06:26PM
Aug-02-21 05:39PM
Jul-28-21 11:22PM
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Shair Matthew Director Apr 22 '24 Sale 63.65 37,500 2,386,910 1,537,198 Apr 24 04:44 PM Conley Emily Director Apr 15 '24 Option Exercise 9.36 5,000 46,800 5,008 Apr 17 04:44 PM Shair Matthew Director Apr 15 '24 Sale 65.56 37,500 2,458,335 1,574,698 Apr 17 04:46 PM Conley Emily Director Apr 15 '24 Sale 65.52 5,000 327,607 8 Apr 17 04:44 PM Shair Matthew Director Apr 08 '24 Sale 68.44 37,500 2,566,479 1,612,198 Apr 10 04:45 PM Miller Deborah Ann Chief Legal Officer Apr 04 '24 Option Exercise 6.89 3,000 20,670 36,300 Apr 05 04:47 PM Miller Deborah Ann Chief Legal Officer Apr 04 '24 Sale 73.60 3,000 220,787 33,300 Apr 05 04:47 PM Shair Matthew Director Apr 01 '24 Sale 76.92 37,500 2,884,337 1,649,698 Apr 03 04:45 PM Miller Deborah Ann Chief Legal Officer Mar 28 '24 Option Exercise 22.58 22,000 496,740 55,300 Mar 29 04:46 PM Miller Deborah Ann Chief Legal Officer Mar 28 '24 Sale 75.20 22,000 1,654,311 33,300 Mar 29 04:46 PM Hack Andrew A. F. Director Mar 27 '24 Sale 72.77 880,000 64,035,959 2,697,267 Mar 29 05:15 PM Shair Matthew Director Mar 25 '24 Sale 76.77 37,500 2,878,982 1,687,198 Mar 27 04:55 PM Shair Matthew Director Mar 25 '24 Sale 76.77 2,000 153,546 238,522 Mar 27 04:55 PM Noci Darlene Chief Development Officer Mar 22 '24 Option Exercise 7.74 20,000 154,800 53,300 Mar 25 04:49 PM Noci Darlene Chief Development Officer Mar 22 '24 Sale 77.51 20,000 1,550,229 33,300 Mar 25 04:49 PM Conley Emily Director Mar 15 '24 Option Exercise 9.36 13,333 124,797 13,341 Mar 19 04:46 PM Conley Emily Director Mar 15 '24 Sale 80.92 13,333 1,078,883 8 Mar 19 04:46 PM Shair Matthew Director Dec 28 '23 Sale 75.46 48,548 3,663,492 1,724,698 Dec 28 05:09 PM Shair Matthew Director Dec 27 '23 Sale 75.17 1,000 75,170 1,773,246 Dec 28 05:09 PM Shair Matthew Director Dec 26 '23 Sale 75.12 69,602 5,228,346 1,774,246 Dec 28 05:09 PM Miller Deborah Ann Chief Legal Officer Dec 19 '23 Option Exercise 18.93 5,000 94,650 5,000 Dec 20 04:54 PM Miller Deborah Ann Chief Legal Officer Dec 19 '23 Sale 75.00 5,000 375,000 0 Dec 20 04:54 PM Miller Deborah Ann Chief Legal Officer Dec 18 '23 Option Exercise 27.85 33,046 920,331 33,046 Dec 20 04:54 PM Noci Darlene Chief Development Officer Dec 18 '23 Option Exercise 4.70 40,000 188,139 40,000 Dec 20 04:56 PM Protopapas Anna Director Dec 18 '23 Option Exercise 9.36 5,000 46,800 5,000 Dec 20 04:58 PM Balcom Alexandra Chief Financial Officer Dec 18 '23 Option Exercise 1.08 30,000 32,400 30,000 Dec 20 04:51 PM Noci Darlene Chief Development Officer Dec 18 '23 Sale 75.82 40,000 3,032,800 0 Dec 20 04:56 PM Miller Deborah Ann Chief Legal Officer Dec 18 '23 Sale 75.82 33,046 2,505,548 0 Dec 20 04:54 PM Balcom Alexandra Chief Financial Officer Dec 18 '23 Sale 75.82 30,000 2,274,600 0 Dec 20 04:51 PM Protopapas Anna Director Dec 18 '23 Sale 75.67 5,000 378,350 0 Dec 20 04:58 PM Shair Matthew Director Nov 28 '23 Sale 61.89 9,150 566,303 1,843,848 Nov 30 04:47 PM Noci Darlene Chief Development Officer Nov 01 '23 Option Exercise 1.08 3,000 3,240 3,000 Nov 03 04:43 PM Noci Darlene Chief Development Officer Nov 01 '23 Sale 52.66 3,000 157,975 0 Nov 03 04:43 PM Shair Matthew Director Oct 24 '23 Sale 50.70 91,700 4,648,872 1,852,998 Oct 26 04:47 PM Noci Darlene Chief Development Officer Oct 04 '23 Option Exercise 5.56 20,000 111,150 20,000 Oct 06 04:56 PM Turner Christopher Durant Chief Medical Officer Oct 04 '23 Option Exercise 6.89 7,995 55,086 22,508 Oct 06 04:58 PM Noci Darlene Chief Development Officer Oct 04 '23 Sale 55.99 20,000 1,119,702 0 Oct 06 04:56 PM Turner Christopher Durant Chief Medical Officer Oct 04 '23 Sale 54.04 7,995 432,031 14,513 Oct 06 04:58 PM Noci Darlene Chief Development Officer Oct 02 '23 Option Exercise 1.08 3,000 3,240 3,000 Oct 04 04:24 PM Noci Darlene Chief Development Officer Oct 02 '23 Sale 45.88 3,000 137,649 0 Oct 04 04:24 PM Miller Deborah Ann Chief Legal Officer Sep 15 '23 Option Exercise 6.89 2,000 13,780 2,000 Sep 19 04:45 PM Miller Deborah Ann Chief Legal Officer Sep 15 '23 Sale 47.64 2,000 95,283 0 Sep 19 04:45 PM Noci Darlene Chief Development Officer Sep 01 '23 Option Exercise 1.08 3,000 3,240 3,000 Sep 06 04:36 PM Noci Darlene Chief Development Officer Sep 01 '23 Sale 46.56 3,000 139,692 0 Sep 06 04:36 PM Miller Deborah Ann Chief Legal Officer Aug 15 '23 Option Exercise 6.89 2,000 13,780 2,000 Aug 17 04:29 PM Miller Deborah Ann Chief Legal Officer Aug 15 '23 Sale 42.65 2,000 85,310 0 Aug 17 04:29 PM Noci Darlene Chief Development Officer Aug 01 '23 Option Exercise 1.08 3,000 3,240 3,000 Aug 01 05:26 PM Noci Darlene Chief Development Officer Aug 01 '23 Sale 49.95 3,000 149,844 0 Aug 01 05:26 PM Balcom Alexandra Chief Financial Officer Jul 31 '23 Option Exercise 1.08 25,000 27,000 25,000 Aug 01 04:16 PM Balcom Alexandra Chief Financial Officer Jul 31 '23 Sale 48.99 25,000 1,224,796 0 Aug 01 04:16 PM Miller Deborah Ann Chief Legal Officer Jul 28 '23 Option Exercise 6.89 6,500 44,785 6,500 Aug 01 04:13 PM Turner Christopher Durant Chief Medical Officer Jul 28 '23 Option Exercise 6.89 2,665 18,362 17,178 Jul 28 04:51 PM Miller Deborah Ann Chief Legal Officer Jul 28 '23 Sale 48.52 6,500 315,380 0 Aug 01 04:13 PM Turner Christopher Durant Chief Medical Officer Jul 28 '23 Sale 48.93 2,665 130,398 14,513 Jul 28 04:51 PM Turner Christopher Durant Chief Medical Officer Jul 26 '23 Option Exercise 6.89 2,365 16,295 16,878 Jul 28 04:51 PM Turner Christopher Durant Chief Medical Officer Jul 26 '23 Sale 46.85 2,365 110,800 14,513 Jul 28 04:51 PM Turner Christopher Durant Chief Medical Officer Jul 24 '23 Option Exercise 6.89 200 1,378 14,713 Jul 24 04:54 PM Turner Christopher Durant Chief Medical Officer Jul 24 '23 Sale 46.82 200 9,364 14,513 Jul 24 04:54 PM Noci Darlene Chief Development Officer Jul 20 '23 Option Exercise 1.08 10,941 11,816 10,941 Jul 21 04:47 PM Turner Christopher Durant Chief Medical Officer Jul 20 '23 Option Exercise 6.89 100 689 14,613 Jul 24 04:54 PM Noci Darlene Chief Development Officer Jul 20 '23 Sale 45.17 10,941 494,205 0 Jul 21 04:47 PM Turner Christopher Durant Chief Medical Officer Jul 20 '23 Sale 46.80 100 4,680 14,513 Jul 24 04:54 PM Noci Darlene Chief Development Officer Jul 19 '23 Option Exercise 1.08 4,559 4,924 4,559 Jul 21 04:47 PM Noci Darlene Chief Development Officer Jul 19 '23 Sale 45.04 4,559 205,337 0 Jul 21 04:47 PM Miller Deborah Ann Chief Legal Officer Jul 17 '23 Option Exercise 6.89 2,000 13,780 2,000 Jul 19 04:43 PM Miller Deborah Ann Chief Legal Officer Jul 17 '23 Sale 43.06 2,000 86,123 0 Jul 19 04:43 PM Noci Darlene Chief Development Officer Jul 03 '23 Option Exercise 1.08 3,000 3,240 3,000 Jul 06 04:51 PM Noci Darlene Chief Development Officer Jul 03 '23 Sale 41.48 3,000 124,427 0 Jul 06 04:51 PM Noci Darlene Chief Development Officer Jun 16 '23 Option Exercise 1.08 2,900 3,132 2,900 Jun 20 04:45 PM Noci Darlene Chief Development Officer Jun 16 '23 Sale 45.19 2,900 131,051 0 Jun 20 04:45 PM Miller Deborah Ann Chief Legal Officer Jun 15 '23 Option Exercise 6.89 2,000 13,780 2,000 Jun 20 04:42 PM Noci Darlene Chief Development Officer Jun 15 '23 Option Exercise 1.08 1,000 1,080 1,000 Jun 20 04:45 PM Miller Deborah Ann Chief Legal Officer Jun 15 '23 Sale 44.28 2,000 88,565 0 Jun 20 04:42 PM Noci Darlene Chief Development Officer Jun 15 '23 Sale 45.07 1,000 45,070 0 Jun 20 04:45 PM Turner Christopher Durant Chief Medical Officer Jun 05 '23 Option Exercise 6.89 10,235 70,519 24,748 Jun 07 04:50 PM Noci Darlene Chief Development Officer Jun 05 '23 Option Exercise 1.08 600 648 600 Jun 07 04:46 PM Turner Christopher Durant Chief Medical Officer Jun 05 '23 Sale 44.86 10,235 459,142 14,513 Jun 07 04:50 PM Noci Darlene Chief Development Officer Jun 05 '23 Sale 45.00 600 27,000 0 Jun 07 04:46 PM Noci Darlene Chief Development Officer Jun 01 '23 Option Exercise 1.08 3,000 3,240 3,000 Jun 02 04:45 PM Noci Darlene Chief Development Officer Jun 01 '23 Sale 42.64 3,000 127,921 0 Jun 02 04:45 PM Miller Deborah Ann Chief Legal Officer May 15 '23 Option Exercise 6.89 2,000 13,780 2,000 May 17 04:44 PM Miller Deborah Ann Chief Legal Officer May 15 '23 Sale 40.74 2,000 81,489 0 May 17 04:44 PM Miller Deborah Ann Chief Legal Officer May 09 '23 Option Exercise 6.89 1,332 9,177 1,332 May 09 05:11 PM Miller Deborah Ann Chief Legal Officer May 09 '23 Sale 39.63 1,332 52,787 0 May 09 05:11 PM Miller Deborah Ann Chief Legal Officer May 05 '23 Option Exercise 6.89 2,800 19,292 2,800 May 09 05:11 PM Miller Deborah Ann Chief Legal Officer May 05 '23 Sale 39.64 2,800 110,992 0 May 09 05:11 PM Miller Deborah Ann Chief Legal Officer May 01 '23 Option Exercise 6.89 900 6,201 900 May 03 04:38 PM Noci Darlene Chief Development Officer May 01 '23 Option Exercise 1.08 3,000 3,240 3,000 May 03 04:41 PM Noci Darlene Chief Development Officer May 01 '23 Sale 38.60 3,000 115,787 0 May 03 04:41 PM Miller Deborah Ann Chief Legal Officer May 01 '23 Sale 39.61 900 35,649 0 May 03 04:38 PM
Index RUT
P/E -
EPS (ttm) -1.50
Insider Own 24.18%
Shs Outstand 120.71M
Perf Week -9.54%
Market Cap 356.62M
Forward P/E -
EPS next Y -0.72
Insider Trans -0.23%
Shs Float 91.97M
Perf Month -34.52%
Income -171.67M
PEG -
EPS next Q -0.18
Inst Own 71.11%
Short Float 11.50%
Perf Quarter -8.70%
Sales 36.85M
P/S 9.68
EPS this Y 55.50%
Inst Trans 4.10%
Short Ratio 4.77
Perf Half Y 164.86%
Book/sh 0.31
P/B 9.62
EPS next Y -9.63%
ROA -61.27%
Short Interest 10.58M
Perf Year -24.42%
Cash/sh 1.72
P/C 1.71
EPS next 5Y -
ROE -266.24%
52W Range 0.80 - 9.62
Perf YTD 26.72%
Dividend Est. -
P/FCF -
EPS past 5Y 11.93%
ROI -263.08%
52W High -69.44%
Beta 1.61
Dividend TTM -
Quick Ratio 3.36
Sales past 5Y 12371.94%
Gross Margin 95.88%
52W Low 266.86%
ATR (14) 0.30
Dividend Ex-Date -
Current Ratio 3.36
EPS Y/Y TTM 31.64%
Oper. Margin -463.86%
RSI (14) 26.46
Volatility 8.50% 7.28%
Employees 123
Debt/Eq 0.92
Sales Y/Y TTM 38.65%
Profit Margin -465.80%
Recom 1.44
Target Price 6.50
Option/Short Yes / Yes
LT Debt/Eq 0.77
EPS Q/Q 63.57%
Payout -
Rel Volume 0.39
Prev Close 2.85
Sales Surprise -27.40%
EPS Surprise 0.12%
Sales Q/Q -27.14%
Earnings Feb 28 BMO
Avg Volume 2.22M
Price 2.94
SMA20 -21.96%
SMA50 -33.02%
SMA200 14.63%
Trades
Volume 858,285
Change 3.16%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-19-24 Upgrade
JP Morgan
Underweight → Neutral
$5
Feb-29-24 Upgrade
Wedbush
Neutral → Outperform
$2 → $7
Feb-29-24 Upgrade
Guggenheim
Neutral → Buy
$7
Feb-29-24 Upgrade
BTIG Research
Neutral → Buy
$6
Dec-04-23 Upgrade
Citigroup
Neutral → Buy
$1 → $5
Jul-28-23 Downgrade
Robert W. Baird
Outperform → Neutral
$7 → $1
Jul-27-23 Downgrade
Wedbush
Outperform → Neutral
Jul-27-23 Downgrade
Truist
Buy → Hold
Jul-27-23 Downgrade
JP Morgan
Neutral → Underweight
Jul-27-23 Downgrade
Guggenheim
Buy → Neutral
Jul-27-23 Downgrade
Citigroup
Buy → Neutral
Jul-27-23 Downgrade
BTIG Research
Buy → Neutral
Jun-16-23 Downgrade
JP Morgan
Overweight → Neutral
$11 → $5
Jun-15-23 Initiated
Guggenheim
Buy
$14
Mar-16-23 Upgrade
JP Morgan
Neutral → Overweight
$10
Jan-20-23 Initiated
Citigroup
Buy
$12
Nov-21-22 Initiated
Truist
Buy
$12
Oct-15-21 Resumed
BTIG Research
Buy
$32
Aug-30-21 Initiated
H.C. Wainwright
Buy
$28
Mar-31-21 Initiated
Credit Suisse
Neutral
$18
Show Previous Ratings
Apr-04-24 04:30PM
Feb-29-24 08:41AM
Feb-28-24 09:49PM
(Thomson Reuters StreetEvents) +13.58%
08:10AM
07:35AM
07:00AM
Loading…
07:00AM
Feb-27-24 08:01AM
Feb-21-24 08:00AM
Feb-20-24 10:00AM
Feb-01-24 08:00AM
Jan-05-24 08:01AM
Dec-01-23 04:30PM
Nov-08-23 02:42PM
12:13AM
(Thomson Reuters StreetEvents)
Nov-07-23 08:10AM
07:00AM
Loading…
07:00AM
Oct-31-23 04:30PM
08:00AM
Sep-07-23 06:30AM
(American City Business Journals)
Sep-06-23 07:00AM
Aug-18-23 09:35AM
Aug-16-23 09:35AM
Aug-08-23 09:40AM
08:00AM
Aug-04-23 04:05PM
Jul-28-23 10:13AM
03:14AM
Jul-27-23 09:34PM
01:44PM
(American City Business Journals)
07:06AM
09:45AM
Loading…
Jul-13-23 09:45AM
Jul-06-23 04:05PM
Jun-22-23 11:04AM
Jun-16-23 10:43AM
02:26AM
Jun-15-23 09:32AM
07:36AM
07:30AM
Jun-13-23 06:00AM
Jun-02-23 04:05PM
May-28-23 09:06AM
May-24-23 08:00AM
May-09-23 08:35AM
07:00AM
May-04-23 04:05PM
May-03-23 08:00AM
May-02-23 08:00AM
Apr-26-23 04:05PM
Apr-19-23 02:42PM
Apr-17-23 11:07AM
Apr-06-23 04:05PM
Apr-05-23 02:00PM
Mar-16-23 11:20AM
Mar-13-23 02:00PM
07:54AM
07:30AM
Mar-10-23 07:10PM
Mar-03-23 04:05PM
Mar-02-23 08:55PM
Mar-01-23 05:24AM
Feb-28-23 11:51PM
(Thomson Reuters StreetEvents) +11.60%
07:00AM
Feb-21-23 08:00AM
Feb-03-23 04:05PM
Feb-02-23 08:00AM
Feb-01-23 08:00AM
Jan-25-23 08:00AM
Jan-20-23 03:16PM
Jan-16-23 02:18AM
Jan-06-23 04:05PM
07:00AM
Dec-31-22 07:42AM
Dec-23-22 12:46PM
(American City Business Journals)
10:08AM
Dec-22-22 04:08PM
04:05PM
Dec-14-22 08:00AM
Dec-02-22 04:05PM
Nov-08-22 08:00AM
Nov-07-22 08:25AM
07:00AM
Nov-04-22 04:05PM
Oct-31-22 08:00AM
Oct-30-22 10:13AM
Oct-17-22 09:40AM
Oct-06-22 04:05PM
Oct-04-22 04:05PM
Sep-30-22 08:02AM
Sep-12-22 08:00AM
Sep-06-22 08:00AM
Sep-02-22 04:05PM
Sep-01-22 10:17AM
Aug-16-22 09:55AM
08:00AM
Aug-12-22 06:05AM
Aug-11-22 11:25AM
Aug-09-22 06:58AM
Aug-08-22 05:15PM
04:04PM
04:02PM
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Protopapas Anna Director Jan 16 '24 Sale 2.71 29,399 79,671 125,153 Jan 17 05:21 PM Lowinger Timothy B SVP, Chief Sci.&Tech. Officer Jan 16 '24 Sale 2.71 10,409 28,208 199,329 Jan 17 05:19 PM DeSchuytner Brian SVP, COO & CFO Jan 16 '24 Sale 2.71 9,327 25,276 54,511 Jan 17 05:18 PM Mandelia Ashish VP, Chief Accounting Officer Jan 16 '24 Sale 2.71 5,025 13,618 23,328 Jan 17 05:20 PM Carvajal Alejandra SVP, Chief Legal Officer Jan 16 '24 Sale 2.71 4,381 11,873 27,403 Jan 17 05:18 PM Bala Mohan SVP, Chief Development Officer Jan 16 '24 Sale 2.71 3,431 9,298 14,052 Jan 17 05:16 PM MISRA TUSHAR SVP, Chief Manuf. Officer Jan 16 '24 Sale 2.71 3,357 9,097 17,966 Jan 17 05:21 PM Lowinger Timothy B SVP, Chief Sci.&Tech. Officer Jan 15 '24 Option Exercise 0.00 15,208 0 209,738 Jan 17 05:19 PM DeSchuytner Brian SVP, COO & CFO Jan 15 '24 Option Exercise 0.00 10,208 0 63,838 Jan 17 05:18 PM Protopapas Anna Director Jan 15 '24 Option Exercise 0.00 38,958 0 154,552 Jan 17 05:21 PM Mandelia Ashish VP, Chief Accounting Officer Jan 15 '24 Option Exercise 0.00 5,352 0 28,353 Jan 17 05:20 PM Mandelia Ashish VP, Chief Accounting Officer Jan 14 '24 Option Exercise 0.00 4,783 0 23,001 Jan 17 05:20 PM MISRA TUSHAR SVP, Chief Manuf. Officer Jan 14 '24 Option Exercise 0.00 1,458 0 21,323 Jan 17 05:21 PM Protopapas Anna Director Jan 14 '24 Option Exercise 0.00 16,750 0 115,594 Jan 17 05:21 PM Carvajal Alejandra SVP, Chief Legal Officer Jan 14 '24 Option Exercise 0.00 2,500 0 31,784 Jan 17 05:18 PM DeSchuytner Brian SVP, COO & CFO Jan 14 '24 Option Exercise 0.00 6,250 0 55,630 Jan 17 05:18 PM Lowinger Timothy B SVP, Chief Sci.&Tech. Officer Jan 14 '24 Option Exercise 0.00 4,792 0 194,530 Jan 17 05:19 PM Lowinger Timothy B SVP, Chief Sci.&Tech. Officer Jan 13 '24 Option Exercise 0.00 9,375 0 189,738 Jan 17 05:19 PM DeSchuytner Brian SVP, COO & CFO Jan 13 '24 Option Exercise 0.00 10,000 0 47,380 Jan 17 05:18 PM Carvajal Alejandra SVP, Chief Legal Officer Jan 13 '24 Option Exercise 0.00 8,958 0 29,284 Jan 17 05:18 PM Bala Mohan SVP, Chief Development Officer Jan 13 '24 Option Exercise 0.00 8,750 0 17,483 Jan 17 05:16 PM Protopapas Anna Director Jan 13 '24 Option Exercise 0.00 31,250 0 98,844 Jan 17 05:21 PM MISRA TUSHAR SVP, Chief Manuf. Officer Jan 13 '24 Option Exercise 0.00 7,083 0 19,865 Jan 17 05:21 PM Mandelia Ashish VP, Chief Accounting Officer Jan 13 '24 Option Exercise 0.00 2,645 0 18,218 Jan 17 05:20 PM Bala Mohan SVP, Chief Development Officer Oct 26 '23 Sale 1.13 1,912 2,161 8,733 Oct 27 04:07 PM Bala Mohan SVP, Chief Development Officer Oct 25 '23 Option Exercise 0.00 6,250 0 10,645 Oct 27 04:07 PM MISRA TUSHAR SVP, Chief Manuf. Officer Aug 17 '23 Sale 1.18 1,908 2,251 11,507 Aug 18 04:01 PM MISRA TUSHAR SVP, Chief Manuf. Officer Aug 16 '23 Option Exercise 0.00 6,250 0 13,415 Aug 18 04:01 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite